Businesswire News Releases
Apr 30, 2024 07:31 ET
TriLink BioTechnologies® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology
TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries. This agreement with L...
Apr 30, 2024 07:30 ET
Cresco Labs to Report First Quarter 2024 Financial Results on May 15, 2024
Cresco Labs Inc. (CSE:CL) (OTCQX:CRLBF) (FSE: 6CQ) (“Cresco” or “Company”), the industry leader in branded cannabis products with a portfolio of America’s most popular brands and the operator of Sunnyside dispensaries, today announced it will report financial results for the first quarter ended March 31st, 2024 on Wednesday, May 15...
Apr 30, 2024 07:30 ET
Ziegler Capital Management Combines with F/m Investments
F/m Investments has completed its reorganization with Ziegler Capital Management (dba ZCM). Both firms are majority-owned by F/m Managers Group. This simplifies our brands and brings F/m Investments’ total assets to $14 billion dollars as of March 31, 2024 and offers clients and partners access to 40 plus strategies across ETFs, mutual funds, and separately managed accounts....
Apr 30, 2024 07:10 ET
Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that effective April 29, 2024, the Compensation Committee of Enanta Pharmaceuticals’ Board of Directors granted employment inducement awards to Matthew P. Kowal...
Apr 30, 2024 07:10 ET
Envoy Research Reveals One-Third of Organizations Struggle with Workplace Management; 53% Lack Necessary Decision-Making Data
Envoy, the only integrated workplace platform that connects people, spaces, and data, today published the eBook, “
Apr 30, 2024 07:07 ET
Facteus Launches Data Sets Highlighting Consumer Cross Shopping Behavior
Facteus, the largest provider of consumer transaction data insights in the alternative data industry, today announced the launch of Consumer Insights. This powerful tool, a part of Facteus’ Win the Week™ product suite, provides unparalleled insights into consumer behavior by leveraging real purchase transaction data from a wide range of retailers....
Apr 30, 2024 07:05 ET
Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, and Repare Therapeutics Inc. (“Repare”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, announced that the fi...
Apr 30, 2024 07:05 ET
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, and Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, today announced that the first patient has bee...
Apr 30, 2024 07:00 ET
95% of Organizations Revamped Their Cybersecurity Strategies in the Last Year
As the digital landscape continues to evolve at an unprecedented speed, organizations are racing to keep pace with revamped cybersecurity strategies. Today, LogRhythm, the company helping security teams stop breaches by turning disconnected data and signals into trustworthy insights, announced the release of its report, “2024 State of the Security Team: Navig...
Apr 30, 2024 07:00 ET
ADM Reports First Quarter 2024 Results, Affirms Full-Year EPS Guidance
ADM (NYSE: ADM) today reported financial results for the quarter ended March 31, 2024....
Apr 30, 2024 07:00 ET
Axion BioSystems Adds Affordable Maestro Volt™ to its Industry-Leading MEA System Lineup
Axion BioSystems today announced the launch of the new Maestro Volt™, an affordable benchtop microelectrode array (MEA) system designed to meet the demands of academic labs with lower throughput needs and limited budgets. Featuring the same ease of use, high-quality controls, and intuitive software synonymous with the Maestro name, the 6-well Maestro Volt is available for both neurological and cardiovascular research applications. The new device expands Axion’s flagship Maestro product line and promises to drive scientific discovery by making MEA technology more broadly available....
Apr 30, 2024 07:00 ET
BTG Pactual Timberland Investment Group raises US$ 1.24 billion for core Latin America timberland strategy, exceeding target size
The BTG Pactual Timberland Investment Group (TIG) announced today that it has finalized fundraising for BTF II, with equity commitments, including co-investments, totaling US$ 1.24 billion, exceeding its target size....
Apr 30, 2024 07:00 ET
ChargeTronix Announces Appointment of VP of Operations and EV Fleet Sales Manager to Scale EV Infrastructure Business
ChargeTronix, a leading global provider of reliable, powerful and intelligent electric vehicle (EV) charging infrastructure, today announced the appointment of
Apr 30, 2024 07:00 ET
Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the appointment of Matthew P. Kowalsky, J.D., as Chief Legal Officer. In this role, he will lead all legal and compliance activities for Enanta, as well as prov...
Apr 30, 2024 07:00 ET
Enlaza Therapeutics Raises $100 Million through Its Series A Financing, Led by the Life Sciences Group of J.P. Morgan Private Capital
Enlaza Therapeutics, the first covalent biologic platform company, today announced a $100 million Series A financing. The financing will be used to further develop Enlaza’s proprietary covalent protein technologies and to support advancement of wholly owned pipeline programs to the clinic....
Apr 30, 2024 07:00 ET
Eversense® CGM System Receives iCGM Designation by the US FDA
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes and Ascensia Diabetes Care, a global diabetes care company, announced that Eversense® has been granted an integrated CGM (iCGM) designation by the US Food and Drug Administration (FDA)....
Apr 30, 2024 07:00 ET
FEDML Empowers On-Premise AI Innovation at DENSO
FEDML, the company providing "Your Generative AI Platform at Scale," today announced its partnership with DENSO, one of the largest automotive suppliers in the world, to empower fully on-premise training, development, and deployment of AI models and applications via
Apr 30, 2024 07:00 ET
Flow Beverage Corp. Announces Annual General Meeting Results
Flow Beverage Corp. (TSX:FLOW; OTCQX:FLWBF) (“Flow” or the “Company”) is pleased to announce the voting results from its annual general meeting of the shareholders (the “Meeting”), held on April 29, 2024. A total of 72,391,043 votes were represented in person or by proxy at the Meeting, constituting approximately 56.68% of the Company’s total issued and outstanding subordinate voting shares and multiple voting shares as of the record date....
Apr 30, 2024 07:00 ET
Laser Photonics Unveils New Compact CleanTech CR-3030 Laser Cleaning System
Laser Photonics Corporation (LPC) (NASDAQ: LASE), a leading global industr...
Apr 30, 2024 07:00 ET
Newron Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced positive top-line results from its potentially pivotal study 008A, evaluating the safety, tolerability and efficacy of evenamide (30 mg bid) in patients with chronic schizophrenia currently being treated with a second-generation antipsychotic including clozapine, but demonstrating an inadequate response to that treatment. The study met its primary endpoint of imp...
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.